Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial
Julio Rosenstock, Carol Wysham, Juan P. Frías, Shizuka Kaneko, Clare J. Lee, Laura Fernández Landó, Huzhang Mao, Xuewei Cui, Chrisanthi A. Karanikas, Vivian T. Thieu
Topics & Concepts
MedicineTolerabilityType 2 diabetesPlaceboClinical endpointDiabetes mellitusInternal medicineRandomized controlled trialBody mass indexAdverse effectEndocrinologyAlternative medicinePathologyDiabetes Treatment and ManagementBariatric Surgery and OutcomesHyperglycemia and glycemic control in critically ill and hospitalized patients